A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Immune Thrombocytopenia
Age: Between 1 - 17 Years
Gender: Male or Female
Newly diagnosed ITP (<3 months from diagnosis (first abnormal platelet count)
Requires pharmacologic treatment from the perspective of the treating clinician.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required